These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 37014824)

  • 1. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
    Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
    Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC.
    Al-Samkari H; Leiva O; Dagogo-Jack I; Shaw A; Lennerz J; Iafrate AJ; Bendapudi PK; Connors JM
    J Thorac Oncol; 2020 Sep; 15(9):1497-1506. PubMed ID: 32437899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of ALK rearrangement and risk of venous thromboembolism in patients with non-small cell lung cancer: A prospective cohort study.
    Dou F; Zhang Y; Yi J; Zhu M; Zhang S; Zhang D; Zhang Y
    Thromb Res; 2020 Feb; 186():36-41. PubMed ID: 31864154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK-Rearranged Non-Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism.
    Zer A; Moskovitz M; Hwang DM; Hershko-Klement A; Fridel L; Korpanty GJ; Dudnik E; Peled N; Shochat T; Leighl NB; Liu G; Feld R; Burkes R; Wollner M; Tsao MS; Shepherd FA
    Clin Lung Cancer; 2017 Mar; 18(2):156-161. PubMed ID: 27913214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer.
    Lee YG; Kim I; Lee E; Bang SM; Kang CH; Kim YT; Kim HJ; Wu HG; Kim YW; Kim TM; Lee KW; Lee SH; Kim DW; Heo DS
    Thromb Haemost; 2014 Jun; 111(6):1112-20. PubMed ID: 24477503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study.
    Roopkumar J; Poudel SK; Gervaso L; Reddy CA; Velcheti V; Pennell NA; McCrae KR; Khorana AA
    J Thromb Haemost; 2021 Mar; 19(3):822-829. PubMed ID: 33314597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Zhu VW; Zhao JJ; Gao Y; Syn NL; Zhang SS; Ou SI; Bauer KA; Nagasaka M
    Lung Cancer; 2021 Jul; 157():147-155. PubMed ID: 34049720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of thromboembolism in non-small-cell lung cancers patients with different oncogenic drivers, including ROS1, ALK, and EGFR mutations.
    Wang HY; Wu SG; Lin YT; Chen CY; Shih JY
    ESMO Open; 2022 Dec; 7(6):100742. PubMed ID: 36493600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
    Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
    J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common genetic driver mutation in NSCLC and their association with thromboembolic events: A retrospective study.
    Lin M; Lu Y; Yu Q; Chen Z; Peng J; Cai X
    Lung Cancer; 2022 Oct; 172():29-34. PubMed ID: 35986977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence of venous thromboembolism among patients with primary lung cancer.
    Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
    J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score.
    Castellón Rubio VE; Segura PP; Muñoz A; Farré AL; Ruiz LC; Lorente JA
    Thromb Res; 2020 Dec; 196():349-354. PubMed ID: 32977135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
    Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
    Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.